Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The
past decade has witnessed an increasingly improved scientific understanding of the …

Apoptosis is a form of programmed cell death that is regulated by the balance between
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …

Abstract Nucleophosmin 1 (NPM1) is a nucleus-cytoplasmic shuttling protein which is
predominantly located in the nucleolus and exerts multiple functions, including regulation of …

In the past few years research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …

Background Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal
prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax …

Interferon gamma (IFNγ) is a critical cytokine known for its diverse roles in immune
regulation, inflammation, and tumor surveillance. However, while IFNγ levels were elevated …

Acute myeloid leukemia may be characterized by a fraction of leukemia stem cells (LSCs)
that sustain disease propagation eventually leading to relapse. Yet, the contribution of LSCs …

Risk stratification in acute myeloid leukemia (AML) remains principle in survival
prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) …

Randomized trials in acute myeloid leukemia (AML) have demonstrated improved survival
by the BCL-2 inhibitor venetoclax combined with azacitidine in older patients, and clinical …